Expression Profile of Endoglin in Different Grades of Endometrial Cancer

被引:14
|
作者
Oplawski, Marcin [1 ,2 ]
Dziobek, Konrad [2 ]
Adwent, Iwona [3 ]
Dftbru, Dariusz [3 ]
Grabarek, Beniamin [1 ]
Zmarzly, Nikola [1 ]
Plewka, Andrzej [1 ,4 ]
Boron, Dariusz [2 ,3 ,5 ]
机构
[1] Med Univ Silesia, Sch Pharm, Dept Mol Biol, Div Lab Med Sosnowiec, Sosnowiec, Poland
[2] Ludwik Rydygier Mem Specialist Hosp, Dept Gynecol & Obstet Gynecol Oncol, Krakow, Poland
[3] Opole Med High Sch, Dept Midwifery, Opole, Poland
[4] Publ Higher Med Profess Sch Opole, Fac Hlth Sci, Opole, Poland
[5] Med Univ Silesia, Sch Med, Dept Histol & Embryol, Div Dent, Zabrze, Poland
关键词
Endometrial cancer; endoglin; angiogenesis; molecular marker; vascular endothelium; immunohistochemistry; ENDOTHELIAL GROWTH-FACTOR; TGF-BETA CORECEPTOR; PROGNOSTIC MARKERS; CD105; EXPRESSION; ANGIOGENESIS; CARCINOMA; VASCULATURE; METASTASIS; PREDICTOR; DIAGNOSIS;
D O I
10.2174/1389201020666181127152605
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Endoglin is a marker of active, proliferating endothelial cells of blood vessels. In many cancers, it is present in both peripheral vessels and vessels located inside the tumor. Endoglin is more specific and sensitive compared to other tumor angiogenesis markers. It is suggested that endoglin can be considered a reliable marker of disease outcome. Objective: The aim of the study was to assess the expression of endoglin and to determine its potential usefulness as a complementary molecular marker of endometrial cancer. Method: The study included 60 women who underwent hysterectomy: 45 with endometrioid endometrial cancer (study group) and 15 without neoplastic changes (control group). The study group was further divided according to the degree of histological differentiation: G1, 17; G2, 15; and G3, 13. The expression of endoglin was determined immunohistochemically with mouse anti-Endoglin monoclonal antibody. The obtained reactions were evaluated using light microscopy. Results: Analysis of endoglin expression in endothelium showed that it reached 145% of the control. In G2, we observed that the endoglin level decreased and was similar to the control, while in G3 it increased and was even higher than in G1. In cancer cells, endoglin expression increased with the grade of endometrial cancer. Conclusion: Endoglin can be considered a valuable complementary molecular marker, allowing to visualize the advancement of the cancer process, including endometrial cancer.
引用
收藏
页码:990 / 995
页数:6
相关论文
共 50 条
  • [21] CD105 expression is an independent predictor of survival in patients with endometrial cancer
    Erdem, Ozlem
    Taskiran, Cagatay
    Onan, M. Anil
    Erdem, Mehmet
    Guner, Haldun
    Ataoglu, Omur
    GYNECOLOGIC ONCOLOGY, 2006, 103 (03) : 1007 - 1011
  • [22] Vascular endothelial growth factor and endoglin expression in colorectal cancer
    Dassoulas, Konstantinos
    Gazouli, Maria
    Theodoropoulos, George
    Christoni, Zoi
    Rizos, Spyros
    Zisi-Serbetzoglou, Adamantia
    Glava, Chrissa
    Karantanos, Theodoros
    Klonaris, Christos
    Karakitsos, Petros
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (05) : 703 - 708
  • [23] NF-κB and COX-2 Expression in Nonmalignant Endometrial Lesions and Cancer
    Faloppa, Carlos Chaves
    Baiocchi, Glauco
    Cunha, Isabela Werneck
    Tavares Guerreiro Fregnani, Jose Humberto
    Bueno Toledo Osorio, Cynthia Aparecida
    Fukazawa, Elza Mieko
    Kumagai, Lillian Yuri
    Badiglian-Filho, Levon
    Souza Pinto, Gabriel Lowndes
    Soares, Fernando Augusto
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2014, 141 (02) : 196 - 203
  • [24] Expression of vascular endothelial growth factor and assessment of microvascular density with CD 34 and endoglin in proliferative endometrium, endometrial hyperplasia, and endometrial carcinoma
    Erdem, O.
    Erdem, M.
    Erdem, A.
    Memis, L.
    Akyol, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2007, 17 (06) : 1327 - 1332
  • [25] Inhibition of Endoglin-GIPC Interaction Inhibits Pancreatic Cancer Cell Growth
    Pal, Krishnendu
    Pletnev, Alexandre A.
    Dutta, Shamit K.
    Wang, Enfeng
    Zhao, Ruizhi
    Baral, Aradhita
    Yadav, Vinod Kumar
    Aggarwal, Suruchi
    Krishnaswamy, Soundararajan
    Alkharfy, Khalid M.
    Chowdhury, Shantanu
    Spaller, Mark R.
    Mukhopadhyay, Debabrata
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (10) : 2264 - 2275
  • [26] Obesity and altered angiogenic-related gene expression in endometrial cancer
    Cobb, Lauren Patterson
    Siamakpour-Reihani, Sharareh
    Zhang, Dadong
    Qin, Xiaodi
    Owzar, Kouros
    Zhou, Chunxiao
    Conrads, Thomas P.
    Maxwell, G. Larry
    Darcy, Kathleen M.
    Bateman, Nicholas W.
    Litzi, Tracy
    Bae-Jump, Victoria
    Secord, Angeles Alvarez
    GYNECOLOGIC ONCOLOGY, 2021, 163 (02) : 320 - 326
  • [27] WT1 Expression Correlates with Angiogenesis in Endometrial Cancer Tissue
    Dohi, Satoshi
    Ohno, Satoshi
    Ohno, Yumiko
    Kyo, Satoru
    Soma, Gen-Ichiro
    Sugiyama, Haruo
    Inoue, Masaki
    ANTICANCER RESEARCH, 2010, 30 (08) : 3187 - 3192
  • [28] Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review
    Sier, Vincent Q.
    van der Vorst, Joost R.
    Quax, Paul H. A.
    de Vries, Margreet R.
    Zonoobi, Elham
    Vahrmeijer, Alexander L.
    Dekkers, Ilona A.
    de Geus-Oei, Lioe-Fee
    Smits, Anke M.
    Cai, Weibo
    Sier, Cornelis F. M.
    Goumans, Marie Jose T. H.
    Hawinkels, Lukas J. A. C.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (09)
  • [29] Expression of endoglin (CD105) in cervical cancer
    Zijlmans, H. J.
    Fleuren, G. J.
    Hazelbag, S.
    Sier, C. F.
    Dreef, E. J.
    Kenter, G. G.
    Gorter, A.
    BRITISH JOURNAL OF CANCER, 2009, 100 (10) : 1617 - 1626
  • [30] Endoglin for Targeted Cancer Treatment
    Lee S. Rosen
    Michael S. Gordon
    Francisco Robert
    Daniela E. Matei
    Current Oncology Reports, 2014, 16